- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01065948
A Feasibility Study to Assess Critical Aspects of Fluorescence Affinity Sensor (FAS) Performance and Safety Over Several Hours (FAS)
February 3, 2016 updated by: BioTex, Inc.
A Feasibility Study to Assess Critical Aspects of FAS Performance and Safety Over Several Hours
The goal of this clinical research study is to learn about a new minimally invasive glucose monitoring device called Fluorescence Affinity Sensor (FAS).
In this study, the FAS will be used to determine its effectiveness for glucose monitoring.
Researchers want to find out how the device performs at two different body sites (forearm and abdomen) over 4 hours.
The safety and comfort level of the device will also be studied.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The FAS glucose monitoring system is a minimally invasive glucose monitoring device which is not yet approved by the FDA.
The FAS system will be used in this study to monitor glucose levels during a glucose tolerance test (GTT) performed in Dr.Orzeck practice.
The FAS measures glucose levels in skin tissue of the forearm or the abdomen at a depth of less than 1 mm by inserting a small needle-like device.
During the 4-hour GTT, the needle-like FAS is left in the skin tissue.
The FAS performance has indicated in prior experiments that it is more stable than competitive commercial glucose-sensing devices.
Due to its unique design, its glucose response is more accurate, and less affected by certain drugs (such as pain medicine).
Study Type
Interventional
Enrollment (Actual)
12
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Texas
-
Houston, Texas, United States, 77025
- Practice of Eric Orzeck, MD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Female and male patients with Type I and II diabetes requiring injectable insulin from age 18-80.
Exclusion Criteria:
- Patients with fasting glucose concentration larger than 200 mg/dL will be excluded from the study.
- Children under the age of 18 will not be included because Texas state law would not allow such participants to give informed consent on their own.
- Patients who are required to take certain medications including corticosteroids, diuretics, anticonvulsants, birth-control pills, non-steroidal anti-inflammatory drugs (NSAIDs) and certain high-blood pressure medications will be excluded from the study.
- Pregnant women or any patient who cannot participate in an oral glucose tolerance test will also be excluded from the study. Presence of pacemaker or defibrillator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Patients
|
monitor interstitial glucose level every 5 min over 4 hours
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
examine accuracy of FAS response to glucose changes in subcutaneous tissue (compared to blood glucose concentrations measured with reference method)
Time Frame: 3 months
|
3 months
|
monitor safety and performance of FAS response in two different body sites (abdomen, forearm)
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
examine insertion site while the FAS is worn, and after seven days of FAS removal
Time Frame: 3 months
|
3 months
|
assess comfort level during FAS insertion, when worn during normal activities, and during FAS removal
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Ralph Dutt-Ballerstadt, Ph.D., BioTex, Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
November 1, 2009
Primary Completion (Actual)
June 1, 2012
Study Completion (Actual)
August 1, 2012
Study Registration Dates
First Submitted
February 8, 2010
First Submitted That Met QC Criteria
February 9, 2010
First Posted (Estimate)
February 10, 2010
Study Record Updates
Last Update Posted (Estimate)
February 4, 2016
Last Update Submitted That Met QC Criteria
February 3, 2016
Last Verified
February 1, 2016
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- FAS-2009-05
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Guang NingRecruitingType 2 Diabetes Mellitus | Type1 Diabetes Mellitus | Monogenetic Diabetes | Pancreatogenic Diabetes | Drug-Induced Diabetes Mellitus | Other Forms of Diabetes MellitusChina
-
University of Trás-os-Montes and Alto DouroCompletedType 2 Diabetes Mellitus | Diabetes-Related ComplicationsPortugal
-
Northern Care Alliance NHS Foundation TrustBrighter ABCompletedDiabetes type1 | Diabetes type2United Kingdom
-
VeraLight, Inc.InLight SolutionsUnknownGestational Diabetes | Insulin Dependent Diabetes | Non Insulin Dependent DiabetesUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
Oregon State UniversitySanofiCompletedType I or Type II Diabetes (Excludes Gestational Diabetes)
-
Taichung Veterans General HospitalNational Health Research Institutes, TaiwanRecruitingDiabetes Complications | Type 2 Diabetes | Maturity-Onset Diabetes of the Young (MODY)Taiwan
-
University of RoehamptonRecruitingType2 Diabetes Mellitus | Pre DiabetesUnited Kingdom
-
University of ReadingCompletedDiabetes, Type 2 | Diabetes Mellitus, Noninsulin-DependentUnited Kingdom, Kuwait
Clinical Trials on Subcutaneous glucose monitoring device
-
Instituto de Investigación Hospital Universitario...Recruiting
-
SinocareIntegrated Medical DevelopmentRecruitingDiabetes MellitusUnited States
-
NYU Langone HealthCompleted
-
Beijing Tsinghua Chang Gung HospitalThe First Affiliated Hospital of Anhui Medical University; Beijing Tiantan... and other collaboratorsRecruitingComprehensive Complication IndexChina
-
Senseonics, Inc.CompletedDiabetes MellitusNetherlands
-
Milton S. Hershey Medical CenterDexCom, Inc.; Children's Miracle NetworkRecruiting
-
Abbott Diabetes CareCompleted
-
Poitiers University HospitalUnknownInsulin Treated Type 2 Diabetes With High Risk of HypoglycemiaFrance
-
University of the PacificRecruitingType 1 Diabetes | Type 2 DiabetesUnited States